GET-73

GET 73 is an investigational new drug, developed by Laboratorio Farmaceutico CT SRL, that is being evaluated for treating alcohol use disorder (AUD). It acts as a negative allosteric modulator (NAM) of the metabotropic glutamate receptor 5 (mGluR5), a receptor system implicated in the neurobiology of addiction and alcohol-related behaviors.^[1][2][3][4]

GET-73

Identifiers
IUPAC name 4-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]butanamide
CAS Number	202402-01-5
PubChem CID	10221200
PubChem SID	8396692
DrugBank	DB12928
ChemSpider	8396692
UNII	U5CLZ223FH
KEGG	D84113
ChEMBL	ChEMBL4297543
Chemical and physical data
Formula	C13H16F3NO2
Molar mass	275.271 g·mol−1
3D model (JSmol)	Interactive image
SMILES COCCCC(=O)NCC1=CC=C(C=C1)C(F)(F)F
InChI InChI=InChI=1S/C13H16F3NO2/c1-19-8-2-3-12(18)17-9-10-4-6-11(7-5-10)13(14,15)16/h4-7H,2-3,8-9H2,1H3,(H,17,18) Key:QLZOWJNFLXSDSH-UHFFFAOYSA-N

Preclinical studies indicate that GET 73 reduces voluntary alcohol intake, diminishes the alcohol deprivation effect, and demonstrates neuroprotective properties against alcohol-induced neurotoxicity in animal models.^[3][2] It has also been evaluated in early-phase human trials for safety and potential efficacy in reducing alcohol craving and consumption.^[5][2]

GET 73 is a more structurally complex analog of GHB.^[6]